In the Claims:

Claims 1-20 (canceled).

Claim 21 (currently amended). A method for enhancing a humoral immune response in a mammal comprising sequentially administering a protein chemokine and a nucleic acid encoding an antigen to said mammal, wherein said chemokine is MCP-4 ~~or a biologically active fraction of MCP-4, and wherein said antigen and said chemokine are not physically linked as a fusion protein~~.

Claim 22 (original). The method of claim 21 wherein said chemokine is recombinant.

Claim 23 (original). The method of claim 21 wherein said chemokine is human.

Claim 24 (original). The method of claim 21 further comprising administering a substance which allows for the slow release of said chemokine at a delivery site.

Claims 25-26 (canceled).

Claim 27 (previously presented). The method of claim 21 wherein said antigen is a tumor associated antigen.

Claim 28 (canceled).

Claim 29 (previously presented). The method of claim 21 wherein said antigen is a bacterial, viral or fungal antigen.

Claim 30 (canceled).

PAGE 7/10 * RCVD AT 1/26/2006 3:08:43 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-6/28 * DNIS:2738300 * CSID:908 298 5405 * DURATION (mm-ss):02-30

Claim 31 (previously presented). The method of claim 27 wherein said tumor associated antigen is selected from the group consisting of Melan-A, tyrosinase, p97, β-HCG, GalNAc., MAGE-1, MAGE-2, MAGE-3, MAGE-4, MAGE-12, MART-1, MUC1, MUC2, MUC3, MUC4, MUC18, CEA, DDC, melanoma antigen gp75, Hker 8, high molecular weight melanoma antigen, K19, Tyr1 and Tyr2, members of the pMel 17 gene family, c-Met, PSA, PSM, α-fetoprotein, thyroperoxidase, gp 100, p53 and telomerase.

Claim 32 (canceled).

Claim 33 (previously presented). The method of claim 21 further comprising administering a combination of GM-CSF and IL-4.

Claim 34 (canceled).

Claim 35 (previously presented). The method of claim 21 further comprising administering a dendritic cell activating agent with said chemokine.

Claim 36 (currently amended). The method of claim 21 wherein said chemokine is administered intradermally, intramuscularly, subcutaneously, or topically~~, or in the form of a vector~~.

Claims 37-68 (canceled).

Claim 69 (previously presented). The method of claim 35 wherein the activating agent is a nucleic acid containing an unmethylated CpG motif.

PAGE 8/10 * RCVD AT 1/26/2006 3:08:43 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-6/28 * DNIS:2738300 * CSID:908 298 5405 * DURATION (mm-ss):02-30